ZA200909080B - Promoterless cassettes for expression of alphavirus structural proteins - Google Patents

Promoterless cassettes for expression of alphavirus structural proteins

Info

Publication number
ZA200909080B
ZA200909080B ZA200909080A ZA200909080A ZA200909080B ZA 200909080 B ZA200909080 B ZA 200909080B ZA 200909080 A ZA200909080 A ZA 200909080A ZA 200909080 A ZA200909080 A ZA 200909080A ZA 200909080 B ZA200909080 B ZA 200909080B
Authority
ZA
South Africa
Prior art keywords
promoterless
cassettes
expression
structural proteins
alphavirus structural
Prior art date
Application number
ZA200909080A
Other languages
English (en)
Inventor
Kurt I Kamrud
Jonathan F Smith
Maureen Maughan
Original Assignee
Alphavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphavax Inc filed Critical Alphavax Inc
Publication of ZA200909080B publication Critical patent/ZA200909080B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200909080A 2007-06-21 2009-12-18 Promoterless cassettes for expression of alphavirus structural proteins ZA200909080B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93663707P 2007-06-21 2007-06-21

Publications (1)

Publication Number Publication Date
ZA200909080B true ZA200909080B (en) 2010-09-29

Family

ID=40156867

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200909080A ZA200909080B (en) 2007-06-21 2009-12-18 Promoterless cassettes for expression of alphavirus structural proteins

Country Status (14)

Country Link
US (2) US8460913B2 (fr)
EP (2) EP2183368B1 (fr)
JP (3) JP5602624B2 (fr)
CN (1) CN101802199B (fr)
AU (1) AU2008266807B2 (fr)
CA (1) CA2689588C (fr)
DK (2) DK2183368T3 (fr)
ES (2) ES2588906T3 (fr)
HK (1) HK1217216A1 (fr)
IL (1) IL202720A (fr)
NZ (1) NZ582495A (fr)
PL (2) PL2183368T3 (fr)
WO (1) WO2008156829A2 (fr)
ZA (1) ZA200909080B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008266807B2 (en) * 2007-06-21 2012-08-16 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
ES2525707T3 (es) 2008-12-01 2014-12-29 Alphavax, Inc. Uso de microRNAs para el control de ácidos nucleicos colaboradores de virus
AU2010234362B2 (en) 2009-04-08 2015-11-26 Alphavax, Inc. Alphavirus replicon particles expressing TRP2
WO2012006378A1 (fr) 2010-07-06 2012-01-12 Novartis Ag Liposomes à lipides ayant une valeur de pka avantageuse pour la délivrance d'arn
CA2804492A1 (fr) 2010-07-06 2012-01-12 Novartis Ag Immunisation de grands mammiferes a l'aide de faibles doses d'arn
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
PT4066856T (pt) 2010-08-31 2023-01-02 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
CN103269713B (zh) * 2010-10-11 2016-01-20 诺华有限公司 抗原递送平台
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
BE1023557B1 (fr) 2014-02-10 2017-05-03 Univercells Sa Systeme, appareil et procede pour la production de biomolecules
JP2019511255A (ja) 2016-01-11 2019-04-25 バーンダリ，インク． マイクロニードル組成物およびそれを使用する方法
WO2017162265A1 (fr) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Arn à réplication trans
WO2017162266A1 (fr) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Réplicon d'arn pour une expression génique polyvalente et efficace
US10538786B2 (en) 2016-04-13 2020-01-21 Janssen Pharmaceuticals, Inc. Recombinant arterivirus replicon systems and uses thereof
AU2017347725B2 (en) * 2016-10-17 2024-01-04 Janssen Pharmaceuticals, Inc. Recombinant virus replicon systems and uses thereof
MX2019006467A (es) 2016-12-05 2019-12-09 Janssen Pharmaceuticals Inc Star Composiciones y métodos para mejorar la expresión génica.
PE20191842A1 (es) 2017-05-08 2019-12-31 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus
US20200277627A1 (en) * 2017-09-13 2020-09-03 Biontech Rna Pharmaceuticals Gmbh Rna replicon for reprogramming somatic cells
EP3681904A1 (fr) * 2017-09-13 2020-07-22 Biontech Cell&Gene Therapies GmbH Réplicon d'arn permettant d'exprimer un récepteur de lymphocyte t ou un récepteur de lymphocyte t artificiel
WO2019115090A1 (fr) 2017-12-15 2019-06-20 Intervet International B.V. Vaccin félin multivalent
US11992526B2 (en) 2017-11-06 2024-05-28 Intervet Inc. Rabies virus vaccine
US11167027B2 (en) 2017-11-06 2021-11-09 Intervet Inc. Multivalent feline vaccine
BR112020008955A2 (pt) 2017-11-06 2020-11-03 Intervet International B.V. vacina felina multivalente
JP2021501761A (ja) 2017-11-06 2021-01-21 インターベット インターナショナル ベー． フェー． ネコ白血病ウイルスワクチン
US11883476B2 (en) 2017-12-04 2024-01-30 Intervet Inc. Canine lyme disease vaccine
EP3720488A1 (fr) 2017-12-04 2020-10-14 Intervet International B.V. Vaccination avec des particules de réplicon et un adjuvant huileux
AU2018380582A1 (en) 2017-12-08 2020-05-07 Intervet International B.V. Feline calicivirus vaccine
JP7346417B2 (ja) 2017-12-18 2023-09-19 インターベット インターナショナル ベー． フェー． ブタインフルエンザａウイルスワクチン
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
KR20200111729A (ko) 2018-01-19 2020-09-29 얀센 파마슈티칼즈, 인코포레이티드 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진
EP3897710A1 (fr) 2018-12-20 2021-10-27 Intervet International B.V. Régime de vaccination de primo-immunisation/rappel
CA3140019A1 (fr) 2019-05-30 2020-12-03 Gritstone Bio, Inc. Adenovirus modifies
US11744887B2 (en) * 2020-03-09 2023-09-05 Arcturus Therapeutics, Inc. Coronavirus vaccine compositions and methods
EP4149532A1 (fr) 2020-05-11 2023-03-22 Intervet International B.V. Vaccin contre le coronavirus 2 du syndrome respiratoire aigu sévère félin
US20230277649A1 (en) 2020-06-19 2023-09-07 Intervet Inc. Swine influenza a virus vaccine comprising two distinct rna replicon particles
US20230248817A1 (en) 2020-06-19 2023-08-10 Intervet Inc. Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus
JP2023530133A (ja) 2020-06-19 2023-07-13 インターベット インターナショナル ベー． フェー． 遺伝子の特定の順序を有する核酸構築物を含むブタインフルエンザａウイルスワクチン
EP4168428A1 (fr) 2020-06-19 2023-04-26 Intervet International B.V. Vaccin contre le virus de la grippe porcine comprenant une construction d'acide nucléique codant pour des antigènes de lignées de virus spécifiques
AU2021320896A1 (en) 2020-08-06 2023-03-23 Gritstone Bio, Inc. Multiepitope vaccine cassettes
MX2023002674A (es) 2020-09-07 2023-04-03 Intervet Int Bv Vacuna del tallo de ha para blancos positivos a anticuerpos ha.
JP2023549787A (ja) 2020-11-12 2023-11-29 インターベット インターナショナル ベー． フェー． キメラコロナウイルススパイクタンパク質をコードする組換えベクターおよびその使用
WO2023072805A1 (fr) 2021-10-25 2023-05-04 Intervet International B.V. Vaccin pour la protection de porcelets contre une infection par le virus de la grippe porcine a

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500673A (ja) * 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US6770283B1 (en) * 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
US20020102273A1 (en) * 1995-08-08 2002-08-01 Robert B. Grieve Use of alphavirus expression vectors to produce parasite anitgens
AU6172194A (en) 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
RU2057377C1 (ru) 1993-08-23 1996-03-27 Уральский электрохимический комбинат Способ переработки оружейного высокообогащенного урана и его сплавов в топливный материал для атомных реакторов
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0711829A3 (fr) 1993-09-15 1997-07-09 Viagene Inc Vecteurs composés d'alphavirus recombinants
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
FR2723849B1 (fr) * 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5639650A (en) 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US6197879B1 (en) * 1995-10-31 2001-03-06 Henkel Corporation Methods of preparing inorganic pigment dispersions
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
AU2809897A (en) * 1996-04-23 1997-11-12 Wistar Institute Of Anatomy And Biology, The Novel human cytomegalovirus dna constructs and uses therefor
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
SK181098A3 (en) 1996-07-01 1999-07-12 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
JP2965908B2 (ja) 1996-07-05 1999-10-18 株式会社精工技研 調温液体シール手段を備える光ディスク成形用金型装置
US5827658A (en) 1996-08-09 1998-10-27 The United States Of America As Reprsented By The Department Of Health And Human Services Isolation of amplified genes via cDNA subtractive hybridization
US5726022A (en) * 1996-11-18 1998-03-10 Lifespan Biosciences, Inc. Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences
BR9713368A (pt) 1996-11-20 2001-09-18 Introgen Therapeutics Inc Processo melhorado para a produção e a purificação de vetores adenovirais
FR2757169B1 (fr) * 1996-12-13 1999-03-05 Inst Nat Sante Rech Med Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5958738A (en) * 1997-03-24 1999-09-28 Roche Diagnostics Corporation Procedure for subtractive hybridization and difference analysis
US6261570B1 (en) 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
GB9716611D0 (en) 1997-08-07 1997-10-08 Cantab Pharmaceuticals Res Ltd Virus preparations and methods
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6197502B1 (en) 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
GB9804632D0 (en) 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
FI106618B (fi) 1998-03-30 2001-03-15 Sandvik Tamrock Oy Sovitelma painenestekäyttöisen iskulaitteen, kuten esimerkiksi rikotuslaitteen yhteydessä
EP1069908B1 (fr) 1998-04-08 2010-02-10 The University of North Carolina at Chapel Hill Vaccin contre le cancer comprenant des particules de replicon d'alphavirus
US6844188B1 (en) * 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
WO1999061643A1 (fr) * 1998-05-27 1999-12-02 University Of Florida Procede de preparation de compositions de virus adeno-associes de recombinaison a l'aide d'un gradient d'iodixananol
WO2000000616A2 (fr) * 1998-06-29 2000-01-06 U.S. Medical Research Institute Of Infectious Diseases Vaccin contre le virus de marburg
US7267823B2 (en) 1998-06-29 2007-09-11 United States Of America As Represented By The Secretary Of The Army Ebola peptides and immunogenic compositions containing same
AU759461B2 (en) 1998-07-10 2003-04-17 U.S. Medical Research Institute Of Infectious Diseases Botulinum neurotoxin vaccine
AU758019B2 (en) * 1998-07-10 2003-03-13 U.S. Medical Research Institute Of Infectious Diseases Anthrax vaccine
US6770479B1 (en) * 1998-07-10 2004-08-03 The United States Of America As Represented By The Secretary Of The Army Anthrax vaccine
WO2000020029A1 (fr) * 1998-10-05 2000-04-13 Genzyme Corporation Genes differemment exprimes dans des cellules cancereuses servant a la mise au point de vaccins contre le cancer
EP1980617A1 (fr) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Expression améliorée de polypeptides HIV et production de particules de type virus
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
ATE465266T1 (de) 1998-12-31 2010-05-15 Novartis Vaccines & Diagnostic Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren
US6329201B1 (en) * 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
EP2196472A3 (fr) 1999-04-14 2011-04-13 Novartis Vaccines and Diagnostics, Inc. Compositions et procédés permettant de générer une réponse immunitaire au moyen de systèmes de vecteurs à base d'alphavirus
US7651998B1 (en) 1999-08-31 2010-01-26 The University Of North Carolina At Chapel Hill Antibody dependent enhancement of Venezuelan Equine Encephalitis vector infection
CA2385823A1 (fr) * 1999-10-01 2001-04-12 Haifeng Chen Production de virus associes a l'adenovirus (aav) recombinants mettant en oeuvre un adenovirus comprenant des genes rep/cap associes a l'adenovirus
US7115391B1 (en) * 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
WO2001092552A2 (fr) 2000-05-31 2001-12-06 Chiron Corporation Procede de purification de particules de replicon des alphavirus
AU2001273313A1 (en) 2000-07-07 2002-01-21 Alphavax, Inc. Alphavirus vectors and virosomes with modified hiv genes for use as vaccines
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
WO2002010578A1 (fr) 2000-07-28 2002-02-07 Visteon Global Technologies, Inc. Agencement d'admission d'air pour un moteur a combustion interne
AU2001293222B2 (en) * 2000-08-29 2007-09-20 Wyeth Holdings Corporation Packaging of positive-strand RNA virus replicon particles
US6982087B2 (en) * 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
DE10049587A1 (de) * 2000-10-06 2002-05-02 Icon Genetics Ag Vektorsystem für Pflanzen
DE10061150A1 (de) * 2000-12-08 2002-06-13 Icon Genetics Ag Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen
US6800289B2 (en) 2000-12-21 2004-10-05 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Strain of the western equine encephalitis virus
CA2434546C (fr) * 2001-01-12 2012-09-11 Chiron Corporation Induction de reponse immunitaire par une particule de replicon de virus chimere de l'encphalomyelite equine du venezuela-sindbis codant un antigene
DE10121283B4 (de) 2001-04-30 2011-08-11 Icon Genetics GmbH, 80333 Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen
US20030232324A1 (en) 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
EP2305299B1 (fr) 2001-05-31 2017-03-01 GlaxoSmithKline Biologicals SA Particules de replicon d'alphavirus chimerique
DE10143237A1 (de) * 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
DE10143238A1 (de) * 2001-09-04 2003-03-20 Icon Genetics Ag Identifizierung eukaryotischer interner Ribosomen-Eingangsstellen (IRES)-Elemente
JP4790984B2 (ja) * 2001-09-06 2011-10-12 アルファヴァックス，インコーポレイテッド アルファウイルスレプリコンベクター系
WO2003083065A2 (fr) 2002-03-25 2003-10-09 University Of North Carolina At Chapel Hill Methodes ameliorees pour la realisation de l'expression a partir de vecteurs d'alphavirus
JP3857195B2 (ja) * 2002-07-09 2006-12-13 株式会社東芝 距離継電装置
AU2003295470A1 (en) * 2002-11-13 2004-06-03 The United States Of America As Represented By The Secretary Of The Navy Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines
CA2509973C (fr) 2002-12-13 2013-02-26 Alphavax, Inc. Particules de replicon d'alphavirus multi-antigenique et procedes
BR122019005271B1 (pt) * 2002-12-13 2020-10-13 Alphavax, Inc. método para a preparação de partículas de replicon de alfavírus (arps)
AU2004223477B2 (en) 2003-03-20 2009-03-26 Alphavax, Inc. Improved alphavirus replicons and helper constructs
US20060099587A1 (en) * 2003-06-20 2006-05-11 Johnston Robert E Alphavirus vectors having attentuated virion structural proteins
AU2004257214B2 (en) 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
US20050208020A1 (en) * 2003-11-12 2005-09-22 Doolan Denise L Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
US7078087B2 (en) * 2003-12-31 2006-07-18 Kimberly-Clark Worldwide, Inc. Wipes with an edge treatment along a leading edge portion
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
AU2005327198B2 (en) * 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
AU2006302794B2 (en) * 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
EP2061508B1 (fr) * 2006-09-12 2014-10-15 Alphavax, Inc. Particules de réplicon d'alphavirus correspondant à des antigènes de protéines utilisées en qualité d'adjuvants immunologiques
AU2008266807B2 (en) 2007-06-21 2012-08-16 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
JP5758632B2 (ja) * 2008-01-24 2015-08-05 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用

Also Published As

Publication number Publication date
JP2014230544A (ja) 2014-12-11
DK2183368T3 (en) 2016-09-05
AU2008266807B2 (en) 2012-08-16
US7850977B2 (en) 2010-12-14
WO2008156829A3 (fr) 2009-03-12
JP5995926B2 (ja) 2016-09-21
CA2689588A1 (fr) 2008-12-24
PL2947149T3 (pl) 2018-09-28
EP2183368A4 (fr) 2011-04-13
JP5602624B2 (ja) 2014-10-08
US20090075384A1 (en) 2009-03-19
WO2008156829A2 (fr) 2008-12-24
EP2183368B1 (fr) 2016-08-10
JP2016198114A (ja) 2016-12-01
DK2947149T3 (en) 2018-06-06
CA2689588C (fr) 2016-08-23
AU2008266807A1 (en) 2008-12-24
CN101802199B (zh) 2012-08-22
PL2183368T3 (pl) 2016-12-30
NZ582495A (en) 2012-05-25
ES2588906T3 (es) 2016-11-07
IL202720A0 (en) 2011-08-01
HK1217216A1 (zh) 2016-12-30
US20100183665A1 (en) 2010-07-22
EP2947149B1 (fr) 2018-02-28
US8460913B2 (en) 2013-06-11
CN101802199A (zh) 2010-08-11
IL202720A (en) 2013-10-31
ES2670813T3 (es) 2018-06-01
EP2947149A1 (fr) 2015-11-25
JP2010530245A (ja) 2010-09-09
EP2183368A2 (fr) 2010-05-12

Similar Documents

Publication Publication Date Title
HK1217216A1 (zh) 用於α病毒結構蛋白表達的無啓動子盒
HK1244823A1 (zh) 用於原生原纖維形式β-澱粉樣蛋白的特定抗體
GB0700523D0 (en) The Stabilisation Of Proteins
EP2172547A4 (fr) Procédé pour l'expression d'un gène spécifique
HK1142095A1 (zh) 使用抗衰老化合物產生蛋白質的方法
PT2598483T (pt) Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos
EP2265605A4 (fr) Procédé de préparation du dexlansoprazole et autres formes polymorphes
EP2160399A4 (fr) Nouveaux procédés d'extraction de protéines tirées des feuilles
EP2342338A4 (fr) Systèmes et procédés de guidage et de modelage magnétique de cellules et de matériaux
EP2327697A4 (fr) Sels de n-ý4-(1-cyanocyclopentyl)phényl¨-2-(4-pyridylméthyl)amino-3-pyridinecarboxamide
SI2346850T1 (sl) Postopek za pripravo dabigatrana in njegovih intermediatov
EP2195309A4 (fr) Polymorphes de sels de l'ésoméprazole
EP2099904A4 (fr) Procédé permettant de générer de nouvelles protéines stabilisées
HK1168127A1 (en) Method of increasing the expression yield of vitamin -dependent proteins
EP2057144A4 (fr) Nouveaux polymorphes de rimonabant
SI2331098T1 (sl) Postopki za dajanje iloperidona
IL226571B (en) Biological catalysts and methods for the synthesis of armodafinil
SG10201406505WA (en) Methods for the detection of fatty-acylated proteins
IL221005A (en) Method for Synthesis of 5-Amino-1-Phenyl-3-Cyano-4-Trifluoromethyl Sulfinyl Phosphorus
PL2328899T3 (pl) Sposoby syntezy pięcio- i sześcio-członowych pierścieni heterocyklicznych
EP2214674A4 (fr) Inhibiteurs de protéines anti-apoptotiques
GB0709037D0 (en) Isolation of proteins
GB0813006D0 (en) The stabilisation of proteins
EE00771U1 (et) Meetod taruvaigu-saialilleaerosooli tootmiseks
ZA200905010B (en) Process for the preparation of 2-substituted-5-(1-alkylthio) alkylpyridines